Suven Life Sciences Limited (SUVEN.BO)
INR 121.7
(2.4%)
INR 121.7
(2.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.22 Billion INR | -1.92% |
| 2022 | -1.31 Billion INR | -4.59% |
| 2021 | -1.26 Billion INR | -50.45% |
| 2020 | -838.73 Million INR | 28.32% |
| 2019 | -1.17 Billion INR | -316.59% |
| 2018 | -280.86 Million INR | -116.77% |
| 2017 | 1.67 Billion INR | 58.36% |
| 2016 | 1.05 Billion INR | 23.51% |
| 2015 | 856.46 Million INR | -44.82% |
| 2014 | 1.55 Billion INR | -25.71% |
| 2013 | 2.08 Billion INR | 361.02% |
| 2012 | 453.17 Million INR | 157.7% |
| 2011 | 175.85 Million INR | 111.95% |
| 2010 | -1.47 Billion INR | -1743.09% |
| 2009 | 89.57 Million INR | -28.25% |
| 2008 | 124.84 Million INR | 19.1% |
| 2007 | 104.82 Million INR | -19.94% |
| 2006 | 130.93 Million INR | 53.94% |
| 2005 | 85.05 Million INR | 34.1% |
| 2004 | 63.42 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -536.63 Million INR | -67.57% |
| 2024 Q1 | -320.24 Million INR | -0.72% |
| 2023 FY | -1.34 Billion INR | -1.92% |
| 2023 Q4 | -317.96 Million INR | 33.47% |
| 2023 Q1 | -296.78 Million INR | 10.59% |
| 2023 Q3 | -477.95 Million INR | -89.39% |
| 2023 Q2 | -252.36 Million INR | 14.97% |
| 2022 Q3 | -532.56 Million INR | -128.39% |
| 2022 FY | -1.31 Billion INR | -4.59% |
| 2022 Q2 | -233.18 Million INR | -2.9% |
| 2022 Q4 | -331.93 Million INR | 37.67% |
| 2022 Q1 | -226.6 Million INR | -8.85% |
| 2021 Q1 | -436.1 Million INR | -103.1% |
| 2021 FY | -1.26 Billion INR | -50.45% |
| 2021 Q4 | -208.18 Million INR | 38.23% |
| 2021 Q3 | -337.01 Million INR | -17.63% |
| 2021 Q2 | -286.51 Million INR | 34.3% |
| 2020 Q1 | -127.61 Million INR | 44.98% |
| 2020 Q2 | -163.9 Million INR | -28.44% |
| 2020 Q3 | -261.57 Million INR | -59.59% |
| 2020 Q4 | -214.72 Million INR | 17.91% |
| 2020 FY | -838.73 Million INR | 28.32% |
| 2019 Q4 | -231.91 Million INR | -2.3% |
| 2019 FY | -1.17 Billion INR | -316.59% |
| 2019 Q3 | -226.69 Million INR | -12.69% |
| 2019 Q1 | -399.36 Million INR | -134.59% |
| 2019 Q2 | -201.16 Million INR | 49.63% |
| 2018 Q4 | 1.15 Billion INR | 924.01% |
| 2018 Q1 | 480.35 Million INR | 0.0% |
| 2018 Q3 | -140.11 Million INR | -224.0% |
| 2018 Q2 | 112.99 Million INR | -76.48% |
| 2018 FY | -280.86 Million INR | -116.77% |
| 2017 FY | 1.67 Billion INR | 58.36% |
| 2016 FY | 1.05 Billion INR | 23.51% |
| 2016 Q4 | 459.21 Million INR | 0.0% |
| 2015 Q3 | 240.85 Million INR | -24.78% |
| 2015 Q4 | 476.21 Million INR | 97.72% |
| 2015 FY | 856.46 Million INR | -44.82% |
| 2015 Q2 | 320.22 Million INR | 17.69% |
| 2015 Q1 | 272.09 Million INR | 947.62% |
| 2014 Q2 | 341.08 Million INR | -35.05% |
| 2014 Q1 | 525.12 Million INR | 21.19% |
| 2014 FY | 1.55 Billion INR | -25.71% |
| 2014 Q4 | 25.97 Million INR | -94.33% |
| 2014 Q3 | 457.85 Million INR | 34.24% |
| 2013 Q1 | 440.92 Million INR | 302.77% |
| 2013 Q4 | 433.3 Million INR | -18.99% |
| 2013 Q3 | 534.86 Million INR | -22.83% |
| 2013 FY | 2.08 Billion INR | 361.02% |
| 2013 Q2 | 693.07 Million INR | 57.19% |
| 2012 Q3 | 130.44 Million INR | 40.31% |
| 2012 Q4 | 109.47 Million INR | -16.08% |
| 2012 FY | 453.17 Million INR | 157.7% |
| 2012 Q1 | 120.29 Million INR | 0.0% |
| 2012 Q2 | 92.96 Million INR | -22.72% |
| 2011 FY | 175.85 Million INR | 111.95% |
| 2010 FY | -1.47 Billion INR | -1743.09% |
| 2009 FY | 89.57 Million INR | -28.25% |
| 2008 FY | 124.84 Million INR | 19.1% |
| 2007 FY | 104.82 Million INR | -19.94% |
| 2006 FY | 130.93 Million INR | 53.94% |
| 2005 FY | 85.05 Million INR | 34.1% |
| 2004 FY | 63.42 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 121.289% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 102.905% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 113.652% |
| Granules India Limited | 6.81 Billion INR | 117.983% |
| Indoco Remedies Limited | 1.29 Billion INR | 194.838% |
| Achyut Healthcare Limited | 4.43 Million INR | 27721.046% |
| Ajanta Pharma Limited | 19.67 Billion INR | 106.23% |
| Alkem Laboratories Limited | 19.46 Billion INR | 106.299% |
| Alpa Laboratories Limited | 184.49 Million INR | 764.413% |
| Brooks Laboratories Limited | 14.44 Million INR | 8589.072% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 171.372% |
| Bajaj HealthCare Limited | - INR | Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 199.579% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 101.81% |
| Eris Lifesciences Limited | 5.18 Billion INR | 123.657% |
| FDC Limited | 2.98 Billion INR | 141.049% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 118.852% |
| Gufic Biosciences Limited | 1.32 Billion INR | 192.173% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 127.73% |
| Ipca Laboratories Limited | 7.98 Billion INR | 115.36% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 341.242% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | -706.69% |
| Lasa Supergenerics Limited | -458 Million INR | -167.644% |
| Laurus Labs Limited | 3.94 Billion INR | 131.044% |
| Lupin Limited | 28.04 Billion INR | 104.371% |
| Mankind Pharma Limited | 21.51 Billion INR | 105.697% |
| Medicamen Biotech Limited | - INR | Infinity% |
| Medico Remedies Limited | 100.3 Million INR | 1322.156% |
| Megasoft Limited | -121.1 Million INR | -912.206% |
| NATCO Pharma Limited | 25.96 Billion INR | 104.722% |
| Piramal Pharma Limited | 4.55 Billion INR | 126.9% |
| RPG Life Sciences Limited | 2.29 Billion INR | 153.476% |
| Sigachi Industries Limited | 1.47 Billion INR | 183.169% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 101.175% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 126.604% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 591.802% |
| Unichem Laboratories Limited | - INR | Infinity% |
| Wanbury Limited | 569.71 Million INR | 315.164% |
| Windlas Biotech Limited | 1.29 Billion INR | 194.375% |
| ZIM Laboratories Limited | 253.82 Million INR | 582.932% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 102.844% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 70.211% |
| Divi's Laboratories Limited | 33.08 Billion INR | 103.706% |
| Hester Biosciences Limited | 364.81 Million INR | 436.017% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 143.999% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 367.913% |
| Bal Pharma Limited | 233.9 Million INR | 624.059% |
| Strides Pharma Science Limited | 5.22 Billion INR | 123.457% |
| Venus Remedies Limited | 534.65 Million INR | 329.275% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 139.187% |
| Nectar Lifesciences Limited | 923.8 Million INR | 232.693% |
| Shilpa Medicare Limited | 1.36 Billion INR | 189.72% |
| Aarti Drugs Limited | 7.14 Billion INR | 117.147% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 176.767% |
| Ind-Swift Limited | 1.22 Billion INR | 199.988% |
| Valiant Laboratories Limited | - INR | Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 108.582% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 68.184% |
| Themis Medicare Limited | 392.58 Million INR | 412.241% |
| Hikal Limited | 32.11 Million INR | 3917.571% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 104.838% |
| Sequent Scientific Limited | - INR | Infinity% |
| Novartis India Limited | 626.5 Million INR | 295.662% |
| Wockhardt Limited | -670 Million INR | -82.959% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 123.623% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | 13617.064% |
| Neuland Laboratories Limited | 5.31 Billion INR | 123.05% |
| Morepen Laboratories Limited | 4.17 Billion INR | 129.369% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | 689.196% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | 4564.353% |